Filing Details

Accession Number:
0001437749-19-007119
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-04-12 18:04:57
Reporting Period:
2019-04-11
Accepted Time:
2019-04-12 18:04:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
72444 Vaxart Inc. VXRT Biological Products, (No Disgnostic Substances) (2836) 591212264
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1652204 Sean Tucker C/O Vaxart, Inc.
290 Utah Ave. Suite 200
South San Francisco CA 94080
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-04-11 27,273 $1.10 52,661 No 4 P Indirect By joint tenancy with Frances Chang and Sean Tucker
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By joint tenancy with Frances Chang and Sean Tucker
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrant (right to buy) Acquisiton 2019-04-11 27,273 $1.10 27,273 $1.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,273 2019-04-11 2024-04-11 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 47,653 Direct
Common Stock 9,060 Indirect By spouse
Footnotes
  1. Each share of common stock was purchased together with a common warrant to purchase one share of the Issuer's common stock at the combined purchase price of $1.10. The Reporting person may not exercise any portion of the common warrant to the extent that he would beneficially own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days' prior notice from the Reporting Person to the Issuer, he may increase the amount of beneficial ownership of outstanding stock after exercising his common warrants up to 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants.